AN2 Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
AN2 Therapeutics, Inc. carries a market capitalization of 115.09M, placing it among publicly traded companies globally.
| Market Cap | 115.09M |
| Enterprise Value | N/A |
Share Statistics
AN2 Therapeutics, Inc. currently has 35.99M shares outstanding.
| Shares Outstanding | 35.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.43 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | -3.41 |
| P/OCF Ratio | -3.41 |
Financial Position
AN2 Therapeutics, Inc. maintains a current ratio of 15.73, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.73 |
| Quick Ratio | 15.33 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -40.93 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
AN2 Therapeutics, Inc.'s stock has gained approximately 285.3211% over the past 52 weeks. The 50-day moving average sits at 4.07, while the 200-day moving average is 2.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | 285.3211% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 2.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -37.12M, while operating income came in at -37.12M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -37.12M |
| Pretax Income | -34.55M |
| Net Income | -34.55M |
| EBITDA | -37.12M |
| EBIT | -37.12M |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
Total book value stands at -250.98M, with working capital of 81.93M providing operational flexibility.
| Cash & Cash Equivalents | 85.29M |
| Total Debt | N/A |
| Net Debt | -53.49M |
| Equity (Book Value) | -250.98M |
| Book Value Per Share | -8.04 |
| Working Capital | 81.93M |
Cash Flow
AN2 Therapeutics, Inc. produced -31.28M in operating cash flow over the past twelve months.
| Operating Cash Flow | -31.28M |
| Capital Expenditures | N/A |
| Free Cash Flow | -31.28M |
| FCF Per Share | -1.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -35.01 |
| FCF Yield | -29.30 |
Scores
AN2 Therapeutics, Inc. posts an Altman Z-Score of 6.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.88 |